

20年の歴史を持つ南米製





20

この会社は19年前からコロンビア市場に進出しており、インビマの認可を受けている。

グアテマラと中央アメリカのさらに5カ国に市場を拡大するために、1つの大きなディストリビューターと真剣に話し合っている。

コロンビアの全主要都市と多くの副次都市に289の提携薬局がある。

CRMは非常によく組織化されており、医師、薬局、機関投資家の間に1397人の会員がいる。コロンビアの全主要都市と多くの副次都市に289の提携薬局がある。

商業市場

- 売上の75%は医師経由
- 売上の25%が機関投資家向け

同社は、原薬、賦形剤、包装、製品を購入し、すべてインビマの認可を受けたコロンビアの専門工場以外注して製造している。

現在、32の製品がインビマと商工省に登録され、承認されている。

2つの新製品がインビマで承認されようとしている。

コロンビアのINVIMAによる承認には、平均2年と3万米ドルの投資が必要である。

この事業には5つの栄養製品があり、私たちはブランドを所有しているが、登録簿は所有していない。

製品紹介

○ 抗生物質

○ 鎮痛薬

抗炎症

○ 抗ヒスタミン薬

心血管系

栄養

消化器内科

○ 脂質低下薬

○ 小児用製品：抗生物質と栄養剤。

TARGET PRICE

\$11,500,000

GROSS REVENUE

\$2,000,000

EBITDA

\$450,000

BUSINESS TYPE

製薬

ESTABLISHED

2002-06-22

SUPPORT & TRAINING

6ヶ月

REASON FOR SELLING

退任

COUNTRY

コロンビア

BUSINESS ID

L#20210109

The information contained herein does not constitute an offer to sell or a solicitation of an offer or a recommendation to purchase securities under the securities laws of any jurisdiction, including the United States Securities Act of 1933, as amended, or any US state securities laws, or a solicitation to enter into any other transaction

The projected financial information contained in the Memorandum is based on judgmental estimates and assumptions made by the management of the target Company, about circumstances and events that have not yet taken place. Accordingly, there can be no assurance that the projected results will be attained. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Memorandum or in relation to the bases and assumptions underlying such projections and you must satisfy yourself in relation to the reasonableness, achievability and accuracy thereof.

By delivering this Memorandum, neither MergersUS Inc., nor its authorized agents are making any recommendations regarding the acquisition or strategies outlined herein. Interested parties shall exercise independent judgment in, and have sole responsibility for, determining whether an acquisition of the Company is suitable for them, and neither MergersUS Inc, nor its authorized agents have responsibility to, and will not, monitor the condition of interested parties to determine that an acquisition is or remains suitable for them. Among other things, suitability of an acquisition will depend upon an interested party's investment and business plans and financial situation.

This document is prepared for information purposes only. It is made available on the express understanding that it will be used for the sole purpose of assisting the recipients to decide whether they wish to proceed with a further investigation of the Proposed Transaction.

The recipients realize and agree that this document is not intended to form the basis of any investment decision or any other appraisal or decision regarding the Proposed Transaction, and does not constitute the basis for the contract which may be concluded in relation to the Proposed Transaction.

All information contained in this document may subsequently be updated and adjusted. MergersUS Inc. has not independently verified any of the information contained herein or on which this document is based. Neither the Company, nor its management or shareholders, nor MergersUS Inc. , nor any of their respective directors, partners, officers, employees or affiliates make any representation or warranty (express or implied) or accept or will accept any responsibility or liability regarding or in relation to the accuracy or completeness of the information contained in this document or any other written or oral information made available to any interested party or its advisers. Any liability in respect of any such information or any inaccuracy in or omission from the document is expressly disclaimed.

www.mergerscorp.com



© 2024 MergersCorp M&A International. All rights reserved.

© 2024 MergersCorp M&A International. MergersCorp™ M&A International is the collective brand name of independent affiliates of MergersCorp M&A International. For more details on the nature of our affiliation, please visit us on our website <https://www.mergerscorp.com/disclaimer>. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws. MergersCorp M&A International does not offer or sell securities or provide investment advice or underwriting services. The articles or publications contained in this presentation are not intended to provide specific business or investment advice. The author or MergersCorp M&A International shall not be liable for any errors or omissions, or for any loss suffered by any person or organization acting or refraining from acting as a result of the content of this website. It is recommended that specific independent advice be sought before making any business or investment decision.



WWW.MERGERSCORP.COM